Last Update: Aug 21, 2026 TulmiSTAR-01: A Two-part, Phase I Dose Escalation and Expansion Followed by a Randomized, Open-label Multicenter, Phase II Study to Assess the Safety and Efficacy of the Combination of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) vs Standard of Care in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer ClinicalTrials.gov Identifier: [NCT07206056](https://clinicaltrials.gov/ct2/show/NCT07206056) Novartis Reference Number:CDZR123A12107 [See if you Pre-qualify](#trial-eligibility "See if you Pre-qualify") All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation. ## Study Description This is a two-part, Phase I/II, open-label, global, multicenter study assessing the safety and efficacy of the combination of tulmimetostat (DZR123) and JSB462 (luxdegalutamide) versus standard of care in participants with progressive metastatic castrate resistant prostate cancer (mCRPC). The Phase 1 study, comprised of Parts 1a and 1b, aims to assess the safety and tolerability of the combination of tulmimetostat and JSB462: 1\. Part 1a is the parallel dose escalation that aims to determine the recommended dose(s) of tulmimetostat and JSB462, in combination, for further exploration. 2\. Part 1b is the dose expansion/optimization that aims to determine the recommended dose of the combination for Phase II. The purpose of the Phase II study (Part 2) is to compare the combination of tulmimetostat with JSB462 in terms of the biochemical response as assessed by PSA50 compared to the standard of care (SoC) in adult men with progressive, taxane-naive mCRPC. Condition Progressive Metastatic Castrate Resistant Prostate Cancer Phase Phase1, Phase2 Overall Status Recruiting Number of Participants188 Start Date Oct 15, 2025 Completion Date Dec 01, 2030 Gender Male Age(s) 18 Years - (Adult, Older Adult) ## Interventions Drug ### JSB462 Dose 1 QD JSB462 Dose 1 QD Drug ### JSB462 Dose 2 QD JSB462 Dose 2 QD Drug ### JSB462 QD The dose of JSB462 QD will be determined based on the totality of data from Part 1a Drug ### Standard of Care (SoC) Androgen Receptor Pathway Inhibitors (ARPI), chemotherapy or Pluvicto (AAA617) at the discretion of the investigator Drug ### Tulmimetostat DL1 QD Part 1a (dose escalation): Doses of tulmimetostat beyond DL1 once a day (QD) will be opened depending on outcome of Dose Escalation Meetings (DEM(s)) Drug ### Tulmimetostat DL2 QD Part 1a (dose escalation): Doses of tulmimetostat beyond DL1 once a day (QD) will be opened depending on outcome of Dose Escalation Meetings (DEM(s)) Drug ### Tulmimetostat DL3 QD Part 1a (dose escalation): Doses of tulmimetostat beyond DL1 once a day (QD) will be opened depending on outcome of Dose Escalation Meetings (DEM(s)) Drug ### Tulmimetostat Doses 1 or 2 QD Part 1b (dose expansion and optimization): tulmimetostat doses 1 or 2 QD Drug ### Tulmimetostat RP2D QD Part 2: tulmimetostat Recommended Phase 2 Dose (RP2D) QD ## Eligibility Criteria Key Inclusion Criteria: \* Participant is an adult man ≥ 18 years of age. \* Participant must have histologically and/or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine or small cell features (current or prior biopsy of the prostate and/or metastatic site). \* Participant must have ≥ 1 metastatic lesion that is present on screening/baseline CT, MRI, or bone scan imaging obtained ≤ 28 days prior to start of treatment (Part 1a dose escalation) or randomization (Part 1b dose expansion and Part 2). \* Participant must have progressive mCRPC. \* Participant must have a castrate level of serum/plasma testosterone (\\< 50 ng/dL or \\< 1.7 nmol/L). \* Prior ARPI therapy: \* Part 1a and 1b only: must have progressed on at least one prior second generation ARPI (abiraterone, enzalutamide, darolutamide, or apalutamide). \* Part 2 only: must have progressed on one prior second generation ARPI (abiraterone, enzalutamide, darolutamide, or apalutamide). \* Prior chemotherapy: \* Part 1a dose escalation only: may have received ≤ 2 prior lines of chemotherapy in CRPC setting. Note: Prior chemotherapy is permitted in the HSPC setting. \* Part 1b dose expansion/optimization only: may have received up to one prior line of chemotherapy in CRPC setting. Note: Prior chemotherapy is permitted in the HSPC setting. \* Part 2 only: Participants must be taxane-naïve in mCRPC setting; prior chemotherapy permitted in HSPC setting only Key Exclusion Criteria: \* Previous treatment with any PRC2 inhibitor, including but not limited to EZH2 inhibitors, EZH2/1 inhibitors, or embryonic ectoderm development (EED) inhibitors. \* Previous treatment with a protein degrader compound that targets the AR. \* Known hypersensitivity or contraindication to any of the study treatment components or its excipients or to drugs of similar chemical classes. \* Treatment with any investigational agent within 28 days (or 5 half-lives, whichever is longer) prior to study entry. \* Previous treatment with radioligand therapy in the mCRPC setting, except in Part 1a where participants may have received RLT in mCRPC setting. \* Participants with evidence of mCRPC or biochemical recurrence / PSA only disease or asymptomatic prostate cancer without known metastatic disease and with no requirement for therapy and with normal PSA for ≥ 1 year prior to study entry. \* Participants with a history of CNS metastases must have received therapy (surgery, radiotherapy, gamma knife) and be neurologically stable, asymptomatic, and not receiving corticosteroids for the purpose of maintaining neurologic integrity. Those with leptomeningeal disease are eligible if those areas have been treated, are stable, and no neurological impairment is present. For those with parenchymal CNS metastasis (or a history of CNS metastasis), baseline and subsequent radiological imaging must include evaluation of the brain with MRI (preferred) or CT with contrast. Other protocol-defined inclusion/exclusion criteria may apply. Australia #### Novartis Investigative Site Recruiting St Leonards,New South Wales,2065,Australia #### Novartis Investigative Site Recruiting Melbourne,Victoria,3000,Australia #### Novartis Investigative Site Recruiting Liverpool,2170,Australia Canada #### Novartis Investigative Site Recruiting Halifax,Nova Scotia,B3h 2y9,Canada China #### Novartis Investigative Site Recruiting Beijing,100021,China Denmark #### Novartis Investigative Site Recruiting Odense C,5000,Denmark #### Novartis Investigative Site Recruiting Vejle,7100,Denmark #### Novartis Investigative Site Recruiting Herlev,2730,Denmark France #### Novartis Investigative Site Recruiting Paris,75231,France #### Novartis Investigative Site Recruiting Paris,75015,France #### Novartis Investigative Site Recruiting Bordeaux,33076,France Germany #### Novartis Investigative Site Recruiting Jena,Thuringia,07740,Germany #### Novartis Investigative Site Recruiting Düsseldorf,North Rhine-Westphalia,40225,Germany Italy #### Novartis Investigative Site Recruiting Padova,PD,35128,Italy #### Novartis Investigative Site Recruiting Orbassano,TO,10043,Italy #### Novartis Investigative Site Recruiting Milan,MI,20133,Italy Malaysia #### Novartis Investigative Site Recruiting Kuching,Sarawak,93586,Malaysia Mexico #### Novartis Investigative Site Recruiting Tlalpan,Mexico City,14050,Mexico Poland #### Novartis Investigative Site Recruiting Poznan,60-192,Poland Singapore #### Novartis Investigative Site Recruiting Singapore,119074,Singapore #### Novartis Investigative Site Recruiting Singapore,308433,Singapore Spain #### Novartis Investigative Site Recruiting Madrid,28041,Spain #### Novartis Investigative Site Recruiting Santiago Compostela,A Coruna,15706,Spain #### Novartis Investigative Site Recruiting Madrid,28009,Spain #### Novartis Investigative Site Recruiting L'Hospitalet de Llobregat,Barcelona,08907,Spain United Kingdom #### Novartis Investigative Site Recruiting London,W1g 6ad,United Kingdom #### Novartis Investigative Site Recruiting Sutton,Surrey,Sm2 5pt,United Kingdom United States #### Duke University Medical Center Recruiting Durham,North Carolina,27710,United States ###### Tykeytra Dale Email: ###### Christopher Hoimes #### Cleveland Clinic Foundation Recruiting Cleveland,Ohio,44195,United States ###### Shilpa Gupta ###### Chandra Taylor Phone: [216-444-0441](tel:216-444-0441) Email: #### Emory University Recruiting Atlanta,Georgia,30329,United States ###### Wilena Session Phone: [404-778-1900](tel:404-778-1900) Email: ###### Jacqueline Brown #### Mass General Hospital Recruiting Boston,Massachusetts,02114,United States ###### Xin Gao ###### Manda Ngin Email: #### Fred Hutchinson Cancer Research Center Recruiting Seattle,Washington,98109-1024,United States ###### Michael Schweizer ###### Ashley Gagnon Phone: [206-606-7486](tel:206-606-7486) Email: #### Sarah Cannon Research Institute Recruiting Denver,Colorado,80218,United States ###### Gerald Falchook ###### Alissa Snow Phone: [720-754-2610](tel:720-754-2610) Email: #### Wichita Urology Group PA Recruiting Wichita,Kansas,67226,United States ###### Tyler Gentry Email: ###### Timothy Richardson #### Sarah Cannon Research Institute Recruiting Jacksonville,Florida,32256,United States ###### Manish Patel ###### Kandyce Trejo Phone: [941-377-9993](tel:941-377-9993) Email: ## Worldwide Contacts If the location of your choosing does not feature any contact detail, please reach out using the information below. #### Novartis Pharmaceuticals Phone: [ +41613241111](tel:+41613241111) Email: #### Novartis Pharmaceuticals Phone: [ 1-888-669-6682](tel:1-888-669-6682) Email: